Drug Trial Radar · NCT05855083
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 1, 2023
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Omeros CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 28 days, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
Conditions
- Thrombotic Microangiopathies
- Hematopoietic Stem Cell Transplantation
Interventions
Biological: narsoplimabDrug
Treatment with narsoplimab 4 mg/kg will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- 100-day survival rate following high-risk HSCT-TMA diagnosis.Time frame: 100 days
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
Omeros Investigational Site
San Diego, California · Recruiting
Omeros Investigational Site
Gainesville, Florida · Not yet recruiting
Omeros Investigational Site
Boston, Massachusetts · Not yet recruiting
Omeros Investigational Site
St Louis, Missouri · Recruiting
Omeros Investigational Site
New York, New York · Not yet recruiting
Omeros Investigational Site
Valhalla, New York · Recruiting
Omeros Investigational Site
Houston, Texas · Not yet recruiting
Omeros Investigational Site
Seattle, Washington · Not yet recruiting
Omeros Investigational Site
Halle, Germany · Not yet recruiting
Omeros Investigational Site
Hanover, Germany · Not yet recruiting
Omeros Investigational Site
Haifa, Israel · Not yet recruiting
Omeros Investigational Site
Jerusalem, Israel · Not yet recruiting
Omeros Investigational Site
Ramat Gan, Israel · Not yet recruiting
Omeros Investigational Site
Tel Aviv, Israel · Not yet recruiting
Omeros Investigational Site
Utrecht, Netherlands · Not yet recruiting
Omeros Investigational Site
Pamplona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.